Hyperion Therapeutics to Present at the Leerink Global Healthcare Conference

Hyperion Therapeutics to Present at the Leerink Global Healthcare Conference

BRISBANE, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics
(Nasdaq:HPTX) announced today that the company is scheduled to present at the
Leerink Global Healthcare Conference on Thursday, February 13 at 2:40 p.m. ET.

Donald J. Santel, chief executive officer, will provide a company overview. To
access the live webcast and subsequent archived recording, please visit
Hyperion's website at http://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, RAVICTI®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company also owns worldwide
rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it
markets in the U.S. The compound is also marketed internationally through
business partners. For more information, please visit www.hyperiontx.com.

CONTACT: Sylvia Wheeler
         Investor Relations and Corporate Communications
         (650) 745-7834
 
Press spacebar to pause and continue. Press esc to stop.